Clinical Trials Using Anti-CTLA4 Monoclonal Antibody BMS-986218
Clinical trials are research studies that involve people. The clinical trials on this list are studying Anti-CTLA4 Monoclonal Antibody BMS-986218. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Patients With Advanced Solid Tumors
The purpose of this study is to determine whether a Monoclonal Antibody both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors
Location: 6 locations
Degarelix Acetate with or without Immunotherapy (BMS-986218) before Surgery for the Treatment of High Risk Localized Prostate Cancer
This early phase I trial studies the side effects and how well degarelix acetate with or without immunotherapy (BMS-986218) before surgery works in treating patients with high risk prostate cancer that has not spread to other parts of the body (localized). Testosterone can cause the growth of prostate cancer cells. Degarelix acetate may help fight prostate cancer by lowering the amount of testosterone made by the body. BMS-986218 is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Giving degarelix acetate and BMS-986218 before surgery may work better in decreasing the chance of prostate cancer coming back compared to degarelix acetate alone.
Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York